- Home
- HEPS vs PCRX Comparison
HEPS vs PCRX Comparison
Compare HEPS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | PCRX |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.4M | 1.0B |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | HEPS | PCRX |
|---|---|---|
| Price | $2.64 | $25.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.07 | ★ $32.86 |
| AVG Volume (30 Days) | 464.2K | ★ 870.9K |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $1,504,533,586.00 | $716,791,000.00 |
| Revenue This Year | $41.69 | $6.24 |
| Revenue Next Year | $29.78 | $9.53 |
| P/E Ratio | ★ N/A | $53.26 |
| Revenue Growth | ★ 56.77 | 3.14 |
| 52 Week Low | $2.15 | $18.17 |
| 52 Week High | $3.85 | $27.64 |
Technical Indicators
Market Signals| Indicator | HEPS | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 49.14 |
| Support Level | $2.46 | $24.20 |
| Resistance Level | $2.58 | $26.81 |
| Average True Range (ATR) | 0.19 | 1.04 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 33.33 | 30.41 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.